$ETNB 89bio Inc Target PTs 29 --> 20 --> 43 and higherNASDAQ:ETNB 89bio Inc
Target PTs 29 --> 20 --> 43 and higher
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB trade ideas
ETNB long (longer-term play)ETNB long, longer-term play
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Pre-revenue, early stage company.
ETNB large insider trading orders info from secform4.com
july8th 275,000 shares bought at $27.5 $7,562,500 dollars worth 10% owner
september 21rst 1,300,000 shares bought at $28 $36,400,000 dollars worth director 10% owner
a few days after had bank of america upgrade from 37 to 43 dollars target posted on finviz.com
in a long position up to around 43 dollars per share